AN OPEN CLINICAL STUDY ON THE EFFICACY OF WITHANIA SOMNIFERA MOTHER TINCTURE IN THE MANAGEMENT OF HYPERLIPIDEMIA

Basavaraj S Adi Basavaraj S Adi; Siva Rami Reddy E Siva Rami Reddy E

Basavaraj S Adi Reader, Department of Pharmacy, Bharatesh Homoeopathic Medical College, Belagavi.
Siva Rami Reddy E Faculty of Homoeopathy, Tantia University, Sri Ganganagar, Rajasthan.

Abstract

Withania somnifera has anti toxidant, anti inflammatory and anti diabetic activities. In the present open clinical study is that efficacy of Withania somnifera mother tincture in hyperlipidemia. Hyperlipidemia patients meeting the inclusion criteria were randomly assigned in to the treatment and placebo.

Methods: 30 all randomized patients in treatment group took Withania somnifera mother tincture; whereas the patients in placebo group took placebo mother tincture for 12 weeks. The lipid profiles, blood pressure of the patients were evaluated at baseline, and after 6 and 12 weeks of the open clinical trial.

Results: The final results showed that Withania somnifera mother tincture significantly p value 0.05 improved LDL, HDL, cholesterol, compared to the placebo group. It had no effect on systolic or diastolic blood pressure was not significant (P > 0.05) compared to placebo. The Withania somnifera showed an inhibitory effect on of hepatic enzymes and possible liver toxicity. No serious side effect was reported for Withania somnifera mother tincture administration. Therefore, Withania somnifera mother tincture could be considered as a supplement for treatment of dyslipidemia.

Keywords: Open clinical study, hyperlipidemia, Withania somnifera

Downloads

Download data is not yet available.

References

1. Vural H, Sabuncu T, Arslan SO, Aksoy N. Melatonin inhibits lipid peroxidation and stimulates the antioxidant status of diabetic rats. J Pineal Res 2001; 31: 193-198.
2. Visavadiya NP, Narasimhacharya AVRL. Hypocholesteremic and antioxidant effects of Withania somnifera (Dunal) in hypercholesteremic rats. Phytomedicine. 2007;14(2-3):136–142.
3. Godi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep 2007; 7(3): 228–234.
4. Brunzell JD, Ayyobi AF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003; 115: 24S-28S.
5. Kerckhoffs DAJM, Brouns F, Hornstra G, Mensink RP. Effects on the human serum lipoprotein profile of β-glucan, soy protein and isoflavones, plant sterols and stanols, garlic and tocotrienols. Journal of Nutrition. 2002;132(9):2494–2505.
6. NRC [National Research Council]. 1996. Guide for the Care and Use ofLaboratory Animals. 7th ed. Washington DC: National Academy Press.
7. Wybenga DR, Pileggi VJ, Dirstine PH, Di Glorgio J. Direct manual determination of serum total cholesterol with a single stable reagent. Clin Chem 1970; 16: 980- 984.
8. Warnick GR, Nguyen T, Albers AA. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem 1985; 31: 217-22.
9. Bucolo G, David M. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 1973; 19: 476-82.
10. Tripathi YB, Singh BK, Pandey RS, Kumar M. BHUX: a patent herbal formulation to prevent atherosclerosis. Evidence-Based Complementary and Alternative Medicine. 2005; 2(2):217–221.
11. Friedewald WT, Levy RL, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
12. Claiborne A. Catalase activity. In: Greenwald, R.A (Ed.). CRC Handbook of Methods for Oxygen Radical Research 1985. CRC Press, Boca Raton, FL, pp. 283-284.
13. Arjmandi, B.H., Ahn, J., Nathani, S., Reeves, R.D., 1992. Soluble dietary fiber and cholesterol affect serum cholesterol concentration, hepatic portal venous shot-chain fatty acid concentrations and fecal sterol excretion in rats. J. Nutr. 122, 246–253.